{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:51:18Z","timestamp":1791895878574,"version":"4.3.4"},"reference-count":316,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmthera.2025.108958","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:46:22Z","timestamp":1763646382000},"page":"108958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["RNA-based drugs: current, imminent and possible therapeutic applications"],"prefix":"10.1016","volume":"277","author":[{"given":"Sebastiano A.","family":"Torrisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Diolos\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: Golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Therapeutics"},{"issue":"40","key":"10.1016\/j.pharmthera.2025.108958_bb0010","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1038\/s41388-023-02801-8","article-title":"A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy","volume":"42","author":"Abdelaal","year":"2023","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0015","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/24741264251367100","article-title":"Real-world experience of geographic atrophy treatment with Avacincaptad Pegol","volume":"9","author":"Abou-Samra","year":"2025","journal-title":"Journal of VitreoRetinal Disease"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0020","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1096\/fj.201700914R","article-title":"Hydroxysteroid (17beta) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice","volume":"32","author":"Adam","year":"2018","journal-title":"The FASEB Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-011-1568-1","article-title":"ErbB1\/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells","volume":"132","author":"Aird","year":"2012","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-025-01145-6","article-title":"Comparing Moderna\u2019s mRNA-1083 and Pfizer\u2019s dual-target mRNA vaccines for influenza and COVID-19","volume":"10","author":"Akingbola","year":"2025","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0045","doi-asserted-by":"crossref","first-page":"2450045","DOI":"10.1080\/21645515.2025.2450045","article-title":"The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)","volume":"21","author":"Akingbola","year":"2025","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"10101","key":"10.1016\/j.pharmthera.2025.108958_bb0050","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"issue":"7966","key":"10.1016\/j.pharmthera.2025.108958_bb0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","volume":"618","author":"Albers","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0065","first-page":"365","article-title":"microRNA (miRNA) speciation in Alzheimer\u2019s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF)","volume":"3","author":"Alexandrov","year":"2012","journal-title":"International Journal of Biochemistry and Molecular Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","article-title":"Recommendations for the diagnosis and treatment of the acute porphyrias","volume":"142","author":"Anderson","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb0080","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/156652312800840621","article-title":"Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: Progress and challenges","volume":"12","author":"Arechavala-Gomeza","year":"2012","journal-title":"Current Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0095","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","article-title":"PCSK9 inhibitor wars: How does Inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection","volume":"24","author":"Arnold","year":"2022","journal-title":"Current Cardiology Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb0105","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbagrm.2018.11.009","article-title":"RNA ribose methylation (2'-O-methylation): Occurrence, biosynthesis and biological functions","volume":"1862","author":"Ayadi","year":"2019","journal-title":"Biochimica et Biophysica Acta, Gene Regulatory Mechanisms"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34 - a microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Frontiers in Genetics"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0125","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jhep.2016.01.035","article-title":"The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis","volume":"64","author":"Bala","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.omtn.2023.07.012","article-title":"Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling","volume":"33","author":"Bala","year":"2023","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0135","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108958_bb0140","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114469","article-title":"Non-coding RNAs: Emerging from the discovery to therapeutic applications","volume":"189","author":"Baptista","year":"2021","journal-title":"Biochemical Pharmacology"},{"issue":"5998","key":"10.1016\/j.pharmthera.2025.108958_bb0150","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1193692","article-title":"miR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants","volume":"329","author":"Baudry","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: A pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney International"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: New roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb0175","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0180","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.molcel.2005.11.009","article-title":"Ribozyme cleavage reveals connections between mRNA release from the site of transcription and pre-mRNA processing","volume":"20","author":"Bird","year":"2005","journal-title":"Molecular Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0185","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/nprot.2007.278","article-title":"A protocol for designing siRNAs with high functionality and specificity","volume":"2","author":"Birmingham","year":"2007","journal-title":"Nature Protocols"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2025.108958_bb0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0195","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00441-006-0190-8","article-title":"The CNS renin-angiotensin system","volume":"326","author":"von Bohlen Und Halbach","year":"2006","journal-title":"Cell and Tissue Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"npj Vaccines"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0205","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/j.pain.0000000000002154","article-title":"Intranasal delivery of an antisense oligonucleotide to the RNA-binding protein HuR relieves nerve injury-induced neuropathic pain","volume":"162","author":"Borgonetti","year":"2021","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0210","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1021\/acsnano.1c05099","article-title":"Delivery of oligonucleotide therapeutics: Chemical modifications, lipid nanoparticles, and extracellular vesicles","volume":"15","author":"Bost","year":"2021","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0220","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2025.10","article-title":"Advancing CRISPR genome editing into gene therapy clinical trials: Progress and future prospects","volume":"27","author":"Cetin","year":"2025","journal-title":"Expert Reviews in Molecular Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0230","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia a using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10713","article-title":"Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles","volume":"10","author":"Chen","year":"2025","journal-title":"Bioengineering & Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7150\/thno.89247","article-title":"Path towards mRNA delivery for cancer immunotherapy from bench to bedside","volume":"14","author":"Chen","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: Assessing the effect of lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0250","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41591-021-01297-7","article-title":"Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: A case report","volume":"27","author":"Cideciyan","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bph.16424","article-title":"Discovery platforms for RNA therapeutics","volume":"182","author":"Ciucci","year":"2025","journal-title":"British Journal of Pharmacology"},{"issue":"26","key":"10.1016\/j.pharmthera.2025.108958_bb0260","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0265","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infection, Genetics and Evolution"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0270","first-page":"844","article-title":"Vaccination to reduce reactivation of herpes simplex virus type 2","volume":"215","author":"Cohen","year":"2017","journal-title":"The Journal of Infectious Diseases"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0275","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41573-023-00829-9","article-title":"tRNA therapeutics for genetic diseases","volume":"23","author":"Coller","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0280","doi-asserted-by":"crossref","first-page":"1304342","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: A novel frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0285","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1007\/s00415-024-12616-6","article-title":"Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: Analysis from NEURO-TTRansform","volume":"271","author":"Conceicao","year":"2024","journal-title":"Journal of Neurology"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb0290","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1021\/acs.jmedchem.9b01927","article-title":"How we think about targeting RNA with small molecules","volume":"63","author":"Costales","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"29","key":"10.1016\/j.pharmthera.2025.108958_bb0295","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1038\/sj.onc.1205570","article-title":"Expression profiling of microdissected pancreatic adenocarcinomas","volume":"21","author":"Crnogorac-Jurcevic","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","article-title":"Molecular mechanisms of action of antisense drugs","volume":"1489","author":"Crooke","year":"1999","journal-title":"Biochimica et Biophysica Acta"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0305","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10374","article-title":"RNA therapeutics in the clinic","volume":"8","author":"Curreri","year":"2023","journal-title":"Bioengineering & Translational Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0320","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.oret.2024.04.023","article-title":"Vision loss reduction with avacincaptad pegol for geographic atrophy: A 12-month post hoc analysis of the GATHER1 and GATHER2 trials","volume":"8","author":"Danzig","year":"2024","journal-title":"Ophthalmology Retina"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0325","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with Nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0330","article-title":"Emerging role of circular RNA-protein interactions. Noncoding","volume":"7","author":"Das","year":"2021","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: Link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0340","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975408","article-title":"An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma","volume":"12","author":"Deng","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0350","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0355","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"The AAPS Journal"},{"issue":"6078","key":"10.1016\/j.pharmthera.2025.108958_bb0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.1215691","article-title":"miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay","volume":"336","author":"Djuranovic","year":"2012","journal-title":"Science"},{"issue":"6213","key":"10.1016\/j.pharmthera.2025.108958_bb0365","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0370","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nature Biotechnology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb0375","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/erv.12.129","article-title":"The challenge of developing a herpes simplex virus 2 vaccine","volume":"11","author":"Dropulic","year":"2012","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.12.009","article-title":"Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses","volume":"35","author":"Du Pont","year":"2019","journal-title":"Current Opinion in Virology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0385","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0390","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18632\/oncotarget.28608","article-title":"INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death","volume":"15","author":"Duurland","year":"2024","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102313","article-title":"Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications","volume":"35","author":"Eftekhari","year":"2024","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0400","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in human B cell lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6287","key":"10.1016\/j.pharmthera.2025.108958_bb0405","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0410","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"The Lancet Infectious Diseases"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0415","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17582024.2024.2402216","article-title":"Tofersen for SOD1 ALS","volume":"14","author":"Everett","year":"2024","journal-title":"Neurodegenerative Disease Management | Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0420","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/s41467-022-31327-y","article-title":"Pervasive translation of circular RNAs driven by short IRES-like elements","volume":"13","author":"Fan","year":"2022","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0425","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13543784.2024.2320700","article-title":"Kallikrein inhibitors for angioedema: The progress of preclinical and early phase studies","volume":"33","author":"Farkas","year":"2024","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"25","key":"10.1016\/j.pharmthera.2025.108958_bb0430","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-42934-2_5","article-title":"mRNA Cancer Vaccines","volume":"209","author":"Fiedler","year":"2016","journal-title":"Recent Results in Cancer Research"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb0440","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"6669","key":"10.1016\/j.pharmthera.2025.108958_bb0445","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0450","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of Mipomersen: A systematic review and Meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0455","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb0460","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/17425255.2023.2266361","article-title":"The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a phase 1\/2 clinical study","volume":"19","author":"Friedman","year":"2023","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","volume":"9","author":"Gagliardi","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): An antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11883-020-00885-1","article-title":"Familial Chylomicronemia syndrome (FCS): Recent data on diagnosis and treatment","volume":"22","author":"Gallo","year":"2020","journal-title":"Current Atherosclerosis Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0485","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2023.07.026","article-title":"First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection","volume":"79","author":"Gane","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0490","doi-asserted-by":"crossref","first-page":"1052625","DOI":"10.3389\/fped.2022.1052625","article-title":"Lumasiran for primary hyperoxaluria type 1: What we have learned?","volume":"10","author":"Gang","year":"2022","journal-title":"Frontiers in Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0495","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay","year":"2022","journal-title":"RNA Biology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.972933","article-title":"Recent advances in aptamer-based targeted drug delivery systems for cancer therapy","volume":"10","author":"Gao","year":"2022","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108958_bb0505","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary Hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"40","key":"10.1016\/j.pharmthera.2025.108958_bb0510","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"European Heart Journal"},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2025.108958_bb0515","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2870","article-title":"Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: Safety and pharmacokinetic results","volume":"45","author":"Gaudet","year":"2024","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0520","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0525","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/biomedicines8120552","article-title":"Advances in cardiovascular biomarker discovery","volume":"8","author":"Ghantous","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0530","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/jrms.JRMS_879_17","article-title":"Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202","volume":"23","author":"Gheysarzadeh","year":"2018","journal-title":"Journal of Research in Medical Sciences\u202f: The Official Journal of Isfahan University of Medical Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0535","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","article-title":"L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: Dose escalation of the phase I\/II GLORIA trial","volume":"15","author":"Giordano","year":"2024","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0540","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41573-022-00407-5","article-title":"Therapeutic RNA-silencing oligonucleotides in metabolic diseases","volume":"21","author":"Goga","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"27","key":"10.1016\/j.pharmthera.2025.108958_bb0545","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0550","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: An observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2025","journal-title":"The Lancet Infectious Diseases"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0555","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Group, V.I.S.i.O.N.C.T","year":"2006","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108958_bb0560","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0008-8749(02)00506-3","article-title":"T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene","volume":"217","author":"Haasch","year":"2002","journal-title":"BIC. Cell Immunol"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0565","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"558","key":"10.1016\/j.pharmthera.2025.108958_bb0575","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108958_bb0580","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb0585","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.4103\/NRR.NRR-D-24-00667","article-title":"Aptamers as new promising entities for therapeutics: Our experience from the neurological diseases","volume":"20","author":"Hernandez-Jimenez","year":"2025","journal-title":"Neural Regeneration Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0590","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41541-024-01017-5","article-title":"A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines","volume":"9","author":"Ho","year":"2024","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0595","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14760584.2025.2487542","article-title":"Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: A pooled phase 1\/2\/3 randomized clinical study","volume":"24","author":"Ho","year":"2025","journal-title":"Expert Review of Vaccines"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0600","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0605","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0610","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0615","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb0620","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes & Development"},{"issue":"6802","key":"10.1016\/j.pharmthera.2025.108958_bb0625","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/35030140","article-title":"Superoxide dismutase as a target for the selective killing of cancer cells","volume":"407","author":"Huang","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105092","article-title":"Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions","volume":"161","author":"Huynh","year":"2020","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0640","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","article-title":"Cost-effectiveness of Nusinersen and universal newborn screening for spinal muscular atrophy","volume":"227","author":"Jalali","year":"2020","journal-title":"The Journal of Pediatrics"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0645","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: A novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"Journal of Drug Targeting"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0650","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/DDDT.S467835","article-title":"Development of Intratumoral drug delivery based strategies for antitumor therapy","volume":"18","author":"Jiang","year":"2024","journal-title":"Drug Design, Development and Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0655","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13063-019-3409-1","article-title":"iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy","volume":"20","author":"de Jong","year":"2019","journal-title":"Trials"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb0660","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0665","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/10409238.2011.614592","article-title":"Chimeric aptamers in cancer cell-targeted drug delivery","volume":"46","author":"Kanwar","year":"2011","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0670","doi-asserted-by":"crossref","first-page":"1465747","DOI":"10.3389\/fneur.2024.1465747","article-title":"Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: A systematic review","volume":"15","author":"Karimi","year":"2024","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0675","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids in Health and Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0680","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nature Reviews. Immunology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb0685","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.25958","article-title":"Aptamers in the therapeutics and diagnostics pipelines","volume":"8","author":"Kaur","year":"2018","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0690","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108958_bb0695","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia a or B who switched from prior BPA\/CFC prophylaxis: The ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108958_bb0700","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1101\/gad.927801","article-title":"Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. Elegans","volume":"15","author":"Ketting","year":"2001","journal-title":"Genes & Development"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0705","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.11m07316","article-title":"The renin-angiotensin pathway in posttraumatic stress disorder: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms","volume":"73","author":"Khoury","year":"2012","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb0710","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0715","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202400902","article-title":"Systemic brain delivery of oligonucleotide therapeutics enhanced by protein corona-assisted DNA cubes","volume":"9","author":"Kim","year":"2025","journal-title":"Small Methods"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0720","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","article-title":"MicroRNA: Trends in clinical trials of cancer diagnosis and therapy strategies","volume":"55","author":"Kim","year":"2023","journal-title":"Experimental & Molecular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0725","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: Rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0730","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bios.2015.06.040","article-title":"Aptamer-based nanobiosensors","volume":"76","author":"Kim","year":"2016","journal-title":"Biosensors & Bioelectronics"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0735","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S1470-2045(12)70073-6","article-title":"microRNAs in cancer management","volume":"13","author":"Kong","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0740","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0745","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nature Medicine"},{"issue":"7607","key":"10.1016\/j.pharmthera.2025.108958_bb0750","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb0755","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial","volume":"79","author":"Kuter","year":"2023","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb0760","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0765","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0770","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0775","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Communications Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0780","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imm.12505","article-title":"CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes","volume":"146","author":"Lazzaro","year":"2015","journal-title":"Immunology"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: A shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0790","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/neurolint16060096","article-title":"Efficacy of Nusinersen treatment in type 1, 2, and 3 spinal muscular atrophy: Real-world data from a single-center study","volume":"16","author":"Lemska","year":"2024","journal-title":"Neurology International"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0795","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clinical and Translational Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0800","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3349\/ymj.2020.61.4.273","article-title":"Nusinersen as a therapeutic agent for spinal muscular atrophy","volume":"61","author":"Li","year":"2020","journal-title":"Yonsei Medical Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0805","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3892\/ijmm.2016.2497","article-title":"MicroRNA-16 suppresses the activation of inflammatory macrophages in atherosclerosis by targeting PDCD4","volume":"37","author":"Liang","year":"2016","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0810","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Design, Development and Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0815","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","article-title":"Nedosiran, a candidate siRNA drug for the treatment of primary Hyperoxaluria: Design, development, and clinical studies","volume":"5","author":"Liu","year":"2022","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0820","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nature Reviews. Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb0825","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","article-title":"Circular RNAs: Characterization, cellular roles, and applications","volume":"185","author":"Liu","year":"2022","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0830","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/1567205016666190503145207","article-title":"Inhibition of microRNA-155 alleviates cognitive impairment in Alzheimer\u2019s disease and involvement of Neuroinflammation","volume":"16","author":"Liu","year":"2019","journal-title":"Current Alzheimer Research"},{"issue":"5689","key":"10.1016\/j.pharmthera.2025.108958_bb0835","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0840","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/pr.2015.38","article-title":"A novel role of angiopoietin-like-3 associated with podocyte injury","volume":"77","author":"Liu","year":"2015","journal-title":"Pediatric Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0845","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13195-023-01264-z","article-title":"Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer\u2019s disease","volume":"15","author":"Liu","year":"2023","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0850","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb0855","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for transfusion-dependent beta-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"10505","key":"10.1016\/j.pharmthera.2025.108958_bb0860","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): Results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb0865","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: A phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0870","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0875","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mus.28372","article-title":"Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis","volume":"71","author":"Lovett","year":"2025","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0880","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5582\/ddt.2025.01031","article-title":"Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels","volume":"19","author":"Lu","year":"2025","journal-title":"Drug Discoveries & Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0885","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41589-024-01645-x","article-title":"The realization of CRISPR gene therapy","volume":"20","author":"Ma","year":"2024","journal-title":"Nature Chemical Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb0890","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0895","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-025-00711-7","article-title":"The Fomivirsen, Patisiran, and Givosiran odyssey: How the success stories may pave the way for future clinical translation of nucleic acid drugs","volume":"39","author":"Mansouri","year":"2025","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb0900","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1089\/hum.2019.090","article-title":"A new era for rare genetic diseases: Messenger RNA therapy","volume":"30","author":"Martini","year":"2019","journal-title":"Human Gene Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0905","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","article-title":"Angiotensin type 1 receptor inhibition enhances the extinction of fear memory","volume":"75","author":"Marvar","year":"2014","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0910","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1021\/acs.chemrev.9b00457","article-title":"Ribozyme chemistry: To be or not to be under high pressure","volume":"120","author":"Maurel","year":"2020","journal-title":"Chemical Reviews"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108958_bb0915","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington\u2019s disease","volume":"389","author":"McColgan","year":"2023","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104858","article-title":"Antibody-oligonucleotide conjugates in cancer therapy: Potential and promise","volume":"215","author":"Meng","year":"2025","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0925","doi-asserted-by":"crossref","first-page":"1565387","DOI":"10.3389\/fgeed.2025.1565387","article-title":"Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology","volume":"7","author":"Menon","year":"2025","journal-title":"Frontiers in Genome Editing"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0930","doi-asserted-by":"crossref","first-page":"8129513","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of Inclisiran: A small interfering ribonucleic acid molecule targeting PCSK9-a narrative review","volume":"2022","author":"Mercep","year":"2022","journal-title":"Cardiovascular Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb0935","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0940","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41416-022-02123-8","article-title":"Synthetic miR-34a against solid tumours: A predictable failure","volume":"128","author":"Mockly","year":"2023","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb0945","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer","volume":"234","author":"Mollaei","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0950","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/dc18-1343","article-title":"Antisense inhibition of glucagon receptor by IONIS-GCGR(Rx) improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy","volume":"42","author":"Morgan","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0955","first-page":"485","article-title":"Antisense inhibition of angiotensinogen with IONIS-AGT-L(Rx): Results of phase 1 and phase 2 studies","volume":"6","author":"Morgan","year":"2021","journal-title":"JACC: Basic to Translational Science"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb0960","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1002\/cncr.26730","article-title":"An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer","volume":"118","author":"Morrow","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb0965","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: Progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjugate Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb0970","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: A phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb0975","first-page":"1085","volume":"34","author":"Mutanome draws Genentech deal","year":"2016","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116691","article-title":"Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders","volume":"175","author":"Naimi","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0985","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","article-title":"Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"Journal of Pediatric Pharmacology and Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122053","article-title":"New applications of lipid and polymer-based nanoparticles for nucleic acids delivery","volume":"13","author":"Niculescu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb0995","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(01)00547-5","article-title":"ATP requirements and small interfering RNA structure in the RNA interference pathway","volume":"107","author":"Nykanen","year":"2001","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1000","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent Cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1005","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.0610731104","article-title":"MicroRNA-155 is induced during the macrophage inflammatory response","volume":"104","author":"O\u2019Connell","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1010","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S1473-3099(24)00615-7","article-title":"12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine","volume":"24","author":"Oda","year":"2024","journal-title":"The Lancet Infectious Diseases"},{"issue":"26","key":"10.1016\/j.pharmthera.2025.108958_bb1015","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038767","article-title":"A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"103","author":"Olatunji","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","article-title":"The therapeutic potential of circular RNAs","volume":"26","author":"O\u2019Leary","year":"2025","journal-title":"Nature Reviews. Genetics"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MOL.0000000000000898","article-title":"Angiopoietin-like 3 inhibition and the liver: Less is more?","volume":"34","author":"Oostveen","year":"2023","journal-title":"Current Opinion in Lipidology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1030","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejcb.2018.06.003","article-title":"A comprehensive review of signal peptides: Structure, roles, and applications","volume":"97","author":"Owji","year":"2018","journal-title":"European Journal of Cell Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1035","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First Global Approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb1045","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (London, England)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12887-024-05290-0","article-title":"Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: A multicenter disease registry study in China","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Pediatrics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1055","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108958_bb1065","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"10423","key":"10.1016\/j.pharmthera.2025.108958_bb1070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.pharmthera.2025.108958_bb1075","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb1080","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1111\/bph.70063","article-title":"Advancing antihypertensive drug development","volume":"182","author":"Pu","year":"2025","journal-title":"British Journal of Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1085","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","article-title":"The Dawn of a new era: Targeting the \u201cUndruggables\u201d with antibody-based therapeutics","volume":"123","author":"Qian","year":"2023","journal-title":"Chemical Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: Powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb1095","article-title":"Efficacy of alirocumab, evolocumab, and inclisiran in patients with hypercholesterolemia at increased cardiovascular risk","volume":"60","author":"Rajtar-Salwa","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and Pembrolizumab for high-risk ductal carcinoma in situ: A phase 1 nonrandomized clinical trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00401-020-02185-z","article-title":"miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer\u2019s disease","volume":"140","author":"Readhead","year":"2020","journal-title":"Acta Neuropathologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1110","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb1115","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1120","first-page":"0045","article-title":"Efficient modulation of exon skipping via antisense circular RNAs","volume":"6","author":"Ren","year":"2023","journal-title":"Research (Wash D C)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of Donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb1130","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/all.16563","article-title":"Patient-reported outcomes in the phase III OASIS-HAE study of Donidalorsen for hereditary angioedema","volume":"80","author":"Riedl","year":"2025","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1135","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1523\/JNEUROSCI.20-10-03705.2000","article-title":"Wild-type huntingtin protects from apoptosis upstream of caspase-3","volume":"20","author":"Rigamonti","year":"2000","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-4939-1221-6_9","article-title":"Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects","volume":"825","author":"Rigo","year":"2014","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"5824","key":"10.1016\/j.pharmthera.2025.108958_bb1145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1139253","article-title":"Requirement of bic\/microRNA-155 for normal immune function","volume":"316","author":"Rodriguez","year":"2007","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1150","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"7963","key":"10.1016\/j.pharmthera.2025.108958_bb1155","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1160","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1165","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1529\/biophysj.104.054080","article-title":"Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides","volume":"89","author":"Roth","year":"2005","journal-title":"Biophysical Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1170","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: A phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nature Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb1175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nature Reviews. Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb1180","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16140","article-title":"Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis","volume":"31","author":"Saini","year":"2024","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1185","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.omtn.2021.11.007","article-title":"Role of circRNA-miRNA-mRNA interaction network in diabetes and its associated complications","volume":"26","author":"Sakshi","year":"2021","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2025.04.010","article-title":"Current and emerging precision therapies for developmental and epileptic encephalopathies","volume":"168","author":"Samanta","year":"2025","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1172\/JCI111390","article-title":"Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin)","volume":"74","author":"Saraiva","year":"1984","journal-title":"The Journal of Clinical Investigation"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb1200","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-alpha, in patients with advanced liver cancer: A first-in-human, multicenter, open-label, Phase I Trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.it.2014.03.004","article-title":"Heterogeneity in immune responses: From populations to single cells","volume":"35","author":"Satija","year":"2014","journal-title":"Trends in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb1210","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioengineering & Translational Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108958_bb1215","doi-asserted-by":"crossref","first-page":"12326","DOI":"10.1093\/nar\/gkaa1085","article-title":"Design and application of circular RNAs with protein-sponge function","volume":"48","author":"Schreiner","year":"2020","journal-title":"Nucleic Acids Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1220","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1225","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41386-020-00923-1","article-title":"The renin-angiotensin system in PTSD: A replication and extension","volume":"46","author":"Seligowski","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1230","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2172","article-title":"Ribozymes, riboswitches and beyond: Regulation of gene expression without proteins","volume":"8","author":"Serganov","year":"2007","journal-title":"Nature Reviews. Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1245","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10072-022-06568-w","article-title":"A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment","volume":"44","author":"Severi","year":"2023","journal-title":"Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.974666","article-title":"Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders","volume":"13","author":"Shah","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1255","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102373","article-title":"Delivering therapeutic RNA into the brain using extracellular vesicles","volume":"35","author":"Shirmast","year":"2024","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1265","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41386-019-0553-y","article-title":"Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms","volume":"45","author":"Shkreli","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1270","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1038\/s41598-025-94984-1","article-title":"Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen","volume":"15","author":"Simonini","year":"2025","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1275","doi-asserted-by":"crossref","first-page":"1541326","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","volume":"19","author":"Singh","year":"2025","journal-title":"Oncology Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1280","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0026-895X(24)05640-2","article-title":"Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression","volume":"66","author":"Siwkowski","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.pharmthera.2025.108958_bb1290","doi-asserted-by":"crossref","first-page":"16375","DOI":"10.1073\/pnas.1113554108","article-title":"Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines","volume":"108","author":"Somwar","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1300","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia a or haemophilia B without inhibitors (ATLAS-A\/B): A multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108958_bb1305","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial Chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108958_bb1310","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: First approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb1315","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41417-023-00659-2","article-title":"Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer","volume":"30","author":"Szenasi","year":"2023","journal-title":"Cancer Gene Therapy"},{"issue":"s2","key":"10.1016\/j.pharmthera.2025.108958_bb1320","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-skipping in Duchenne muscular dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1325","doi-asserted-by":"crossref","first-page":"422","DOI":"10.18632\/oncotarget.27894","article-title":"Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology","volume":"12","author":"Telford","year":"2021","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1330","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-019-0700-3","volume":"25","author":"The cost of getting personal","year":"2019","journal-title":"Nature Medicine"},{"issue":"11\u221212","key":"10.1016\/j.pharmthera.2025.108958_bb1335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/prca.201200042","article-title":"Aptamers and the next generation of diagnostic reagents","volume":"6","author":"Thiviyanathan","year":"2012","journal-title":"Proteomics. Clinical Applications"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1340","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtn.2022.01.008","article-title":"Cancer immunomodulation using bispecific aptamers","volume":"27","author":"Thomas","year":"2022","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108958_bb1345","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1350","doi-asserted-by":"crossref","first-page":"1008684","DOI":"10.3389\/fmicb.2022.1008684","article-title":"mRNA vaccines: A novel weapon to control infectious diseases","volume":"13","author":"Tian","year":"2022","journal-title":"Frontiers in Microbiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1355","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3350\/cmh.2020.0162","article-title":"Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort","volume":"27","author":"Ting","year":"2021","journal-title":"Clinical and Molecular Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108958_bb1360","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1365","doi-asserted-by":"crossref","first-page":"566","DOI":"10.25259\/JNRP_356_2023","article-title":"Guidelines for pharmacotherapy in Alzheimer\u2019s disease - a primer on FDA-approved drugs","volume":"14","author":"Varadharajan","year":"2023","journal-title":"Journal of Neurosciences in Rural Practice"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb1370","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108625","article-title":"Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms","volume":"9","author":"Vickers","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/imr.12057","article-title":"miR-155: An ancient regulator of the immune system","volume":"253","author":"Vigorito","year":"2013","journal-title":"Immunological Reviews"},{"issue":"9557","key":"10.1016\/j.pharmthera.2025.108958_bb1385","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1390","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1021\/jm901489k","article-title":"Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue","volume":"53","author":"Wancewicz","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1395","doi-asserted-by":"crossref","first-page":"1570000","DOI":"10.3389\/fphar.2025.1570000","article-title":"A crucial role of miR-155 in the pathomechanism of acute kidney injury","volume":"16","author":"Wang","year":"2025","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1400","doi-asserted-by":"crossref","first-page":"8504238","DOI":"10.1155\/2020\/8504238","article-title":"Overexpression of MicroRNA-16 alleviates atherosclerosis by inhibition of inflammatory pathways","volume":"2020","author":"Wang","year":"2020","journal-title":"BioMed Research International"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1405","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-like 3: From discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108958_bb1410","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/acs.chemrev.4c00142","article-title":"Mechanisms and delivery of tRNA therapeutics","volume":"124","author":"Ward","year":"2024","journal-title":"Chemical Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb1415","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent Chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"10427","key":"10.1016\/j.pharmthera.2025.108958_bb1420","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1425","doi-asserted-by":"crossref","first-page":"1113484","DOI":"10.3389\/fped.2023.1113484","article-title":"Angiopoietin-like protein 3: A novel potential biomarker for nephrotic syndrome in children","volume":"11","author":"Wen","year":"2023","journal-title":"Frontiers in Pediatrics"},{"issue":"9\u201310","key":"10.1016\/j.pharmthera.2025.108958_bb1430","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00335-015-9565-z","article-title":"CRISPR-Cas9-mediated genome editing and guide RNA design","volume":"26","author":"Wiles","year":"2015","journal-title":"Mammalian Genome"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108958_bb1435","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108958_bb1440","doi-asserted-by":"crossref","DOI":"10.3390\/genes15070821","article-title":"Preparing for patient-customized N-of-1 antisense oligonucleotide therapy to treat rare diseases","volume":"15","author":"Wilton-Clark","year":"2024","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb1445","article-title":"Recent advances in nanoparticulate RNA delivery systems","volume":"121","author":"Witten","year":"2024","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1450","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial Chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108958_bb1455","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1460","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bioactmat.2021.05.038","article-title":"Delivery of therapeutic oligonucleotides in nanoscale","volume":"7","author":"Wu","year":"2022","journal-title":"Bioactive Materials"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb1465","article-title":"A randomized, double-blind, controlled phase III clinical trial to evaluate the immunogenicity and safety of a lyophilized human rabies vaccine (Vero cells) in healthy participants aged 10-60 years following Essen and Zagreb vaccination procedures","volume":"11","author":"Wu","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"35","key":"10.1016\/j.pharmthera.2025.108958_bb1470","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1021\/acs.jpclett.2c01998","article-title":"S2 subunit of SARS-CoV-2 spike protein induces domain fusion in natural pulmonary surfactant monolayers","volume":"13","author":"Xu","year":"2022","journal-title":"Journal of Physical Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1475","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108958_bb1480","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Advanced Healthcare Materials"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108958_bb1485","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2018.07.003","article-title":"Aptamers: Uptake mechanisms and intracellular applications","volume":"134","author":"Yoon","year":"2018","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1495","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: A closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108958_bb1500","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1510","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: Principles, Progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacological Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1515","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1894","article-title":"The clinical progress and challenges of mRNA vaccines","volume":"15","author":"Yu","year":"2023","journal-title":"Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108958_bb1520","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/brain\/awad349","article-title":"Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model","volume":"147","author":"Yuan","year":"2024","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108958_bb1525","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nature Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108958_bb1530","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of Bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1535","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108958_bb1540","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108958_bb1545","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2326-6066.CIR-16-0303","article-title":"Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade","volume":"5","author":"Zboralski","year":"2017","journal-title":"Cancer Immunology Research"},{"issue":"37","key":"10.1016\/j.pharmthera.2025.108958_bb1550","doi-asserted-by":"crossref","first-page":"15206","DOI":"10.1039\/D3NR02175K","article-title":"Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides","volume":"15","author":"Zeng","year":"2023","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108958_bb1555","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","article-title":"MicroRNA-34 family: A potential tumor suppressor and therapeutic candidate in cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108958_bb1560","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050941","article-title":"Recent advances in aptamer discovery and applications","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108958_bb1565","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1039\/D2TB02782H","article-title":"mRNA therapeutics for disease therapy: Principles, delivery, and clinical translation","volume":"11","author":"Zhou","year":"2023","journal-title":"Journal of Materials Chemistry B"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1570","doi-asserted-by":"crossref","DOI":"10.4161\/rdis.29515","article-title":"FUS-regulated RNA metabolism and DNA damage repair: Implications for amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis","volume":"2","author":"Zhou","year":"2014","journal-title":"Rare Disease"},{"key":"10.1016\/j.pharmthera.2025.108958_bb1575","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jconrel.2023.09.032","article-title":"Protein-based delivery systems for RNA delivery","volume":"363","author":"Zhu","year":"2023","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108958_bb1580","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"Journal of Clinical Lipidology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:39:35Z","timestamp":1766111975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":316,"alternative-id":["S0163725825001706"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108958","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-based drugs: current, imminent and possible therapeutic applications","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108958"}}